DATHYRCA guidelines - Dahanca
DATHYRCA guidelines - Dahanca
DATHYRCA guidelines - Dahanca
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Guidelines - Thyreoideacancer – revideret oktober 2005<br />
70. Hegedus L. Clinical practice. The thyroid nodule. N.Engl.J.Med. 2004;351:1764-71.<br />
71. Schlumberger M, Pacini F. Thyroid tumors. Paris: Éditions Nucléon, 2003:1-317.<br />
72. Mazzaferri EL. Management of a solitary thyroid nodule [see comments]. N.Engl.J.Med. 1993;328:553-<br />
9.<br />
73. Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and<br />
future perspectives. Endocr.Rev. 2003;24:102-32.<br />
74. Hamburger JI. Diagnosis of thyroid nodules by fine needle biopsy: use and abuse.<br />
J.Clin.Endocrinol.Metab 1994;79:335-9.<br />
75. Raber W, Kaserer K, Niederle B, Vierhapper H. Risk factors for malignancy of thyroid nodules initially<br />
identified as follicular neoplasia by fine-needle aspiration: results of a prospective study of one hundred<br />
twenty patients. Thyroid 2000;10:709-12.<br />
76. Christensen L, Blichert-Toft M, Brandt M, Lange M, Sneppen SB, Ravnsbaek J et al. Thyroperoxidase<br />
(TPO) immunostaining of the solitary cold thyroid nodule. Clin.Endocrinol.(Oxf) 2000;53:161-9.<br />
77. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A et al. Application of an immunodiagnostic<br />
method for improving preoperative diagnosis of nodular thyroid lesions. Lancet<br />
2001;357:1644-50.<br />
78. Ashcraft MW, Van Herle AJ. Management of thyroid nodules. II: Scanning techniques, thyroid suppressive<br />
therapy, and fine needle aspiration. Head Neck Surg. 1981;3:297-322.<br />
79. Cases JA, Surks MI. The changing role of scintigraphy in the evaluation of thyroid nodules.<br />
Semin.Nucl.Med. 2000;30:81-7.<br />
80. Hahm JR, Lee MS, Min YK, Lee MK, Kim KW, Nam SJ et al. Routine measurement of serum calcitonin<br />
is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases.<br />
Thyroid 2001;11:73-80.<br />
81. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L et al. Impact of routine measurement of<br />
serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients<br />
with nodular thyroid disorders. J.Clin.Endocrinol.Metab 2004;89:163-8.<br />
82. Singer PA, Cooper DS, Daniels GH, Ladenson PW, Greenspan FS, Levy EG et al. Treatment <strong>guidelines</strong><br />
for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association.<br />
Arch.Intern.Med. 1996;156:2165-72.<br />
83. Redding AH, Levine SN, Fowler MR. Normal preoperative calcitonin levels do not always exclude<br />
medullary thyroid carcinoma in patients with large palpable thyroid masses. Thyroid 2000;10:919-22.<br />
84. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-11.<br />
85. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid<br />
carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically<br />
treated at one institution during 1940 through 1989. Surgery 1993;114:1050-7.<br />
86. Akslen LA. Prognostic importance of histologic grading in papillary thyroid carcinoma. Cancer<br />
1993;72:2680-5.<br />
87. Herrera MF, Hay ID, Wu PS, Goellner JR, Ryan JJ, Ebersold JR et al. Hurthle cell (oxyphilic) papillary<br />
54
Change language